{"id":1702,"date":"2025-05-14T13:08:04","date_gmt":"2025-05-14T13:08:04","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T18:41:01","modified_gmt":"2026-06-26T18:41:01","slug":"1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/","title":{"rendered":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation"},"content":{"rendered":"\n<p><strong>Montreal and Quebec City, QC, May 14, 2025<\/strong>&nbsp;\u2013 9Bio Therapeutics, a biotech company pioneering next-generation oncology therapeutics, and Vega BioImaging, a startup developing innovative companion diagnostics for cancer treatments, are pleased to announce a collaborative $1.8 million initiative in targeted oncology therapies. The project has received significant support from the Government of Quebec, in the form of a $0.9 million grant through CQDM\u2019s Partenar-IA program, in partnership with IVADO.<\/p>\n\n\n\n<p>This initiative combines the complementary strengths of both companies to accelerate the development of a companion diagnostic and a corresponding oncology therapeutic candidate, with an initial focus on treating head, neck, and metastatic breast cancers \u2013 where many patients still lack access to effective treatment options.<\/p>\n\n\n\n<p>9Bio Therapeutics is expanding its pipeline with a second program that leverages its engineering platform to design a conditionally active antibody-drug conjugate (ADC). This novel ADC capitalizes on a clinically validated oncology therapy that was abandoned due to on-target, off-tumor toxicity. Designed to eliminate chemotherapy-resistant tumor cells, it aims to overcome previous safety limitations while preserving promising efficacy observed in three Phase 1 human trials.<\/p>\n\n\n\n<p>Vega BioImaging complements this approach with an advanced diagnostic platform that combines nanotechnology, high-resolution optics, and AI analytics to enable precise biomarker detection. Vega\u2019s technology is designed to address the high rate of companion diagnostic errors \u2013 ranging from 7% to 30% depending on the pathology \u2013 caused by a lack of quantitativity. These errors often lead to sub-optimal treatment prescriptions, which the platform seeks to prevent by improving patient selection for clinical trials and treatment decisions. Vega will support 9Bio by developing a personalized companion diagnostic kit tailored to assess patient inclusion criteria and predict treatment response accurately. This will enhance patient stratification and significantly increase the likelihood of clinical trial success.<\/p>\n\n\n\n<p>\u201cOur goal at 9Bio has always been to develop safe and efficacious treatments that address the real needs of cancer patients,\u201d said Philipe Gobeil, co-founder of 9Bio Therapeutics. \u201cThis partnership allows us to build on that mission with an incredible and complimentary collaborator like Vega, supported by organizations that recognize the urgency of innovation in oncology.\u201d<\/p>\n\n\n\n<p>\u201cOur collaboration with 9Bio allows us to validate our companion diagnostic tools in a real-world therapeutic development scenario, further demonstrating the clinical value and impact of our platform,\u201d said C\u00e9cile Darviot, CEO of Vega BioImaging.<\/p>\n\n\n\n<p>While this collaboration brings together synergistic expertise, each company will fully retain its own intellectual property, balancing collaborative development and independent value creation while advancing novel oncology solutions.<\/p>\n\n\n\n<p>The project is set to make significant strides toward more effective cancer innovation with the potential to improve the chances of survival and quality of life of cancer patients suffering from aggressive and hard-to-treat cancer types. By bringing together companies from different regions of the province and uniting the best of their technologies, this initiative showcases the strength of collaborations within Quebec and positions the province at the forefront of global life science advancement.<\/p>\n\n\n\n<p>\u201cQuebec continues to stand out as a fertile ground for research and innovation, supported by a robust ecosystem that guides companies through every stage of their growth. We are proud to support this collaborative project, which leverages the cutting-edge expertise of our companies and multidisciplinary approaches to expand the range of therapeutic options and diagnostic tools available to people living with cancer,\u201d said V\u00e9ronique Dugas, President and CEO of CQDM.<\/p>\n\n\n\n<p>\u201cIVADO is proud to support this initiative that puts artificial intelligence at the service of tomorrow\u2019s healthcare. By combining advanced protein modeling and precision medicine, this project paves the way for more targeted and better-tolerated treatments, with a meaningful impact on patients facing complex cancers,\u201d added Nancy Laram\u00e9e, Director of Partnerships at IVADO.<\/p>\n\n\n\n<p>Read the official CQDM press release&nbsp;<a href=\"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-ivado-and-two-quebec-based-companies-join-forces-to-advance-ai-driven-oncology-therapies-and-companion-tests\/\" rel=\"noreferrer noopener\" target=\"_blank\">here<\/a>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>About 9Bio Therapeutics<\/strong><\/p>\n\n\n\n<p>9Bio Therapeutics is a biotech company committed to developing innovative oncology therapeutics. Our AI-guided structural biology platform integrates anatomical and biochemical contexts to design drugs that selectively target tumors. Using this approach, we generate medicines with specificity for tumors that spare healthy tissues, improving safety, efficacy, and opening the door to previously underexploited therapeutic modalities. Our pipeline includes two discovery-stage therapies: an antibody-drug conjugate (ADC) targeting chemoresistant tumor cells and an ADC targeting tumor-subverted immune cells.<\/p>\n\n\n\n<p><strong>About Vega BioImaging<\/strong><\/p>\n\n\n\n<p>Vega BioImaging is transforming cancer diagnostics with the first quantitative multi-protein imaging platform, combining nanotechnology and artificial intelligence. Our patented technology detects multiple biomarkers with unmatched sensitivity in both tissue and cytological samples, while seamlessly integrating into existing pathology workflows. The result: more reliable diagnostics, better patient stratification, and fewer clinical trial failures. Learn more at&nbsp;<a href=\"https:\/\/vegabioimaging.com\/\" rel=\"noreferrer noopener\" target=\"_blank\">https:\/\/vegabioimaging.com<\/a>.<\/p>\n\n\n\n<p><strong>About CQDM<\/strong><\/p>\n\n\n\n<p><em>Biopharma Innovation Facilitator<\/em><\/p>\n\n\n\n<p>CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate collaborative multi-stakeholder research and development aimed at accelerating the translation or transformation of innovative technologies into solutions to unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, consult our website&nbsp;<a href=\"https:\/\/cqdm.org\/en\/\" rel=\"noreferrer noopener\" target=\"_blank\">https:\/\/cqdm.org\/en\/<\/a>&nbsp;and join us on Twitter\/X @CQDM_Canada and LinkedIn.<\/p>\n\n\n\n<p><strong>Partenar-IA<\/strong>&nbsp;is a program providing direct support to Quebec companies for collaborative biopharmaceutical R&amp;D projects based on artificial intelligence and applicable to the biopharmaceutical sector.<\/p>\n\n\n\n<p><strong>About IVADO<\/strong><\/p>\n\n\n\n<p>IVADO is an interdisciplinary, cross-sectoral research and knowledge mobilization consortium whose mission is to develop and promote a robust, reasoning and responsible AI. Led by Universit\u00e9 de Montr\u00e9al with four university partners (Polytechnique Montr\u00e9al, HEC Montr\u00e9al, Universit\u00e9 Laval and McGill University), IVADO brings together research centers, government bodies and industry members to co-build ambitious cross-sectoral initiatives with the goal of fostering a paradigm shift for AI and its adoption. For more information, please visit our website at&nbsp;<a href=\"https:\/\/ivado.ca\/en\/\" rel=\"noreferrer noopener\" target=\"_blank\">https:\/\/ivado.ca\/en\/<\/a>.<\/p>\n\n\n\n<p><a href=\"https:\/\/9bio.ca\/news\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/\">Read the original press release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Montreal and Quebec City, QC, May 14, 2025&nbsp;\u2013 9Bio Therapeutics, a biotech company pioneering next-generation oncology therapeutics, and Vega BioImaging, a startup developing innovative companion diagnostics for cancer treatments, are [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1697,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"company":[89],"class_list":["post-1702","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-portfolio-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation | adMare\" \/>\n<meta property=\"og:description\" content=\"Montreal and Quebec City, QC, May 14, 2025&nbsp;\u2013 9Bio Therapeutics, a biotech company pioneering next-generation oncology therapeutics, and Vega BioImaging, a startup developing innovative companion diagnostics for cancer treatments, are [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-14T13:08:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T18:41:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation\",\"datePublished\":\"2025-05-14T13:08:04+00:00\",\"dateModified\":\"2026-06-26T18:41:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/\"},\"wordCount\":959,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"articleSection\":[\"Portfolio Companies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/\",\"name\":\"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"datePublished\":\"2025-05-14T13:08:04+00:00\",\"dateModified\":\"2026-06-26T18:41:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation | adMare","og_description":"Montreal and Quebec City, QC, May 14, 2025&nbsp;\u2013 9Bio Therapeutics, a biotech company pioneering next-generation oncology therapeutics, and Vega BioImaging, a startup developing innovative companion diagnostics for cancer treatments, are [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/","og_site_name":"adMare","article_published_time":"2025-05-14T13:08:04+00:00","article_modified_time":"2026-06-26T18:41:01+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation","datePublished":"2025-05-14T13:08:04+00:00","dateModified":"2026-06-26T18:41:01+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/"},"wordCount":959,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","articleSection":["Portfolio Companies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/","name":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","datePublished":"2025-05-14T13:08:04+00:00","dateModified":"2026-06-26T18:41:01+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=1702"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1702\/revisions"}],"predecessor-version":[{"id":1703,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1702\/revisions\/1703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/1697"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=1702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=1702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=1702"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=1702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}